On behalf of the NIH Common Fund, we’ve just released a new funding opportunity announcement soliciting applications for the Diversity Program Consortium Dissemination and Translation Awards (DPC DaTA) (U01).
This initiative is designed to broaden the DPC’s national impact. It provides an opportunity for institutions not currently part of the DPC to apply for funding to employ the consortium’s experimental methods to understand the effectiveness of biomedical research training, mentoring, or research capacity building interventions.
Continue reading “Funding Opportunity: Diversity Program Consortium Dissemination and Translation Awards (DPC DaTA) and Webinar”
UPDATE: The slides [PDF, 350KB] from the SPAD Webinar have been posted.
We’ve just released a new funding opportunity announcement (FOA) soliciting applications for the Diversity Program Consortium’s Sponsored Programs Administration Development (SPAD) Program (UC2).
A primary goal of the program is to enhance faculty and student participation in biomedical research and research training programs. These programs include undergraduate research programs, Academic Research Enhancement Awards (R15), and Support of Competitive Research (SC1, SC2, SC3), among others. Funded institutions are expected to develop offices that provide services such as professional development in targeted areas (e.g., enhancing grant-writing skills), pre- and post-award services, and certification-guided training of sponsored program staff and leadership.
Continue reading “Funding Opportunity: Sponsored Programs Administration Development (SPAD) Program and Webinar”
Are you preparing an NIH Science Education Partnership Award (SEPA) (R25) application for the July 9 receipt date? If so, please join us for a webinar about the program and the opportunity to ask questions:
Continue reading “Webinar for NIH Science Education Partnership Award (SEPA) Applicants”
Wednesday, June 5, 2:00-3:00 p.m. ET
Sepsis is a serious condition that affects about 1.7 million people and causes about 270,000 deaths annually in the U.S. Because it involves multiple organ systems, it is also one of the clinical research areas supported by NIGMS. Despite decades of research, sepsis remains a poorly understood condition with limited diagnostic tools or therapeutic interventions.
Nearly a year ago, we established a working group of our Advisory Council to advise us on how best to advance sepsis research. At last week’s Council meeting, Dr. John Younger and Dr. Monica Kraft, co-chairs of the working group, presented the group’s recommendations:
Continue reading “Recommendations of the NAGMS Working Group on Sepsis”
As announced earlier in the fiscal year, NIGMS is offering administrative supplements to NIGMS-funded R01, R35, and R37 awards for the purchase of single pieces of equipment.
The deadline for these supplement applications has been extended to June 25, 2019.
Continue reading “Extended Deadline to June 25: NIGMS Administrative Supplements for Equipment”
Prospective applicants frequently ask us whether their application ideas fit within our mission. NIGMS supports basic research that increases our understanding of biological processes and lays the foundation for advances in disease diagnosis, treatment, and prevention. We also support research in some specific clinical areas that affect multiple organ systems, including anesthesia, sepsis, wound healing, and trauma. In addition, we’re committed to training the next generation of scientists, enhancing the diversity of the scientific workforce, and developing research capacity throughout the country.
Not all applications for fundamental biomedical research projects will ultimately be assigned to NIGMS. Other NIH institutes and centers (ICs) also have strong commitments to basic research that underlie an understanding of their own particular organ systems, diseases, or treatments. Each NIH IC is different and supports distinct research areas, so it’s wise to seek advice from the program where your science best fits. Before submitting an application to NIGMS, we strongly recommend that you contact the program director whose portfolio most closely matches your area of research.
Continue reading “Does your application fit the scientific mission of NIGMS?”
NIGMS, along with 11 other NIH institutes and centers, is seeking Small Business Innovation Research (SBIR) applications to develop methods that improve the reproducibility of human induced pluripotent stem cell (iPSC) derivation, growth, and differentiation (RFA-GM-19-001). Human iPSCs are mature cells that have been reprogrammed to an embryonic stem cell-like state and are able to differentiate into any cell type in the body. iPSCs are increasingly important research systems with a wide variety of applications, including studies of human development, tissue regeneration and repair, disease processes, and the development of new therapeutics. iPSCs and other regenerative technologies also have potential to transform clinical practice by creating living, functional tissues to repair or replace tissues or organs lost due to age, disease, damage, or congenital defects. Realizing the full potential of human iPSCs for both research and clinical practice has been limited by the significant variability in reprogramming efficiency, differentiation potential, and cell growth and stability. This funding opportunity announcement (FOA) will support SBIR projects to develop novel, reliable, and cost-effective methods to standardize and increase the utility and reproducibility of iPSCs at all stages, from their derivation to their research and clinical applications.
Continue reading “Funding Opportunity: Methods to Improve Reproducibility of iPSC Derivation, Growth, and Differentiation”
For the past few months, NIGMS has been reviewing its HIV/AIDS grant portfolio. As the HIV/AIDS field has matured and the necessary research directions have become clearer, the HIV/AIDS-related grants we’ve supported have, appropriately, become more narrowly focused. Because of this, and after close consultation with leadership at the National Institute of Allergy and Infectious Diseases (NIAID), we’ve concluded that it’s in the best interest of the research to transition NIGMS’ HIV/AIDS portfolio to NIAID to allow improved scientific coordination, prioritization, and efficiency of management.
Continue reading “NIGMS-Managed HIV/AIDS Research Transitioning to NIAID”